GLP-1s Just Got Stronger — Type 2 Diabetes Is Still Winning
Right now, in New Orleans, 12,000 of the world’s top diabetes researchers are gathered at the ADA 2026 Scientific Sessions. The headlines pouring out of that meeting this week are dominated by one thing: GLP-1 drugs got bigger. The 25 mg dose of the latest incretin therapies produced larger A1c